Acasti Pharma

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

Amarin Corporation Plc

The lucrative addressable market for therapeutics to treat hypertriglyceridemia is expected to increase in future years due to an unhealthy diet, sedentary lifestyles, and prevalence of obesity.

Acasti Pharma And Amarin In Severe Hypertriglyceridemia

LAVAL, Québec, Oct.  01, 2019  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 2019 Cantor Fitzgerald Global Healthcare Conference being held on October 2-4, 2019 at the InterContinental New York Barclay Hotel in New York City. Jan D’Alvise, Chief Executive Officer, is scheduled to present on Wednesday, October 2, 2019 at 7:45 a.m. Eastern Time with one-on-one meetings being held throughout the day.

Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

LAVAL, Quebec, Sept.  09, 2019  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”)  (NASDAQ: ACST – TSX-V: ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company has been awarded up to $750,000 in non-dilutive and non-repayable funding, as well as technical and business advisory services, from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to apply towards research and development of the Company’s unique commercial production platform for CaPre. With NRC IRAP support, Acasti aims to expand and enhance its production capabilities for CaPre.

Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

LAVAL, Québec, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 21st Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City. Jan D’Alvise, Chief Executive Officer, is scheduled to present on Monday, September 9, 2019 at 9:35 a.m. Eastern Time.

Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

LAVAL, Quebec, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), announces the voting results for the matters listed in its management circular dated July 24, 2019 held at its Annual and Special Meeting of Shareholders, in Laval, Canada on August 27, 2019 (the “AGM”). 

Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

Acasti is a small Canadian company being touted by some people as an Amarin competitor.

Acasti Pharma: Another Fish Oil Derived Product Nearing The Market

Acasti Pharma, Inc. (ACST) CEO Janelle D' Alvise on Q1 2020 Results - Earnings Call Transcript

As a follow up to my piece from June 25, 2019, “Home-run Hitters, At Bat With Acasti Pharma”, price target increase from $8.33/share to $11.06/share.

More Players All-In With Acasti Pharma

Acasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2019 Results - Earnings Call Transcript

Shares of biopharmaceutical company Acasti Pharma Inc (NASDAQ: ACST) were trading higher Wednesday after the biopharmaceutical company issued a fiscal 2019 year-end business update.

Acasti Pharma Trades Higher Despite 'Material Uncertainty'

ACST’s drug, CaPre, promises to be the best-in-class Omega 3 play, used to lower triglycerides. It was recently trading at $1.01/share, with a market cap of $79M.

Home-Run Hitters, At Bat With Acasti Pharma

News for Acasti Pharma Stock (ACST)